Proventus e magno iudicio clinico ostendit se adiectionem blinatumomab (Blincyto) ad curationem hominum per acuta lymphoblastic leukemia (ALL) qui in remissione sunt, etiam si nulla signa sunt morbi, diutius eos iuvare possunt.
In tablino, blinatumomab dans una cum chemotherapy, homines cum cancro in remissionem abierant multo longiores vivunt quam illi qui solum chemotherapy obtinuerunt, quae regulam hodiernam curationis habet. Aegroti in iudicio non solum in remissione erant, sed etiam cancri signum nullum erat. Hoc dicitur habentem RELICTUM morbus minimum (MR) Negative OMNES.
Eventus iudicii ostensus est in annuo conventu Societatis Americae Hematologiae (ASH) in New Orleans mense Decembri anno 2022 .
In 2018, the Food and Drug Administration (FDA) cleared blinatumomab to treat people with MRD-positive ALL who were in remission but still showed signs of cancer during follow-up tests. Even though recurrences after remission are always possible, people with MRD-positive ALL have a higher chance of their cancer coming back after their first treatment than those who do not have MRD.
In conventu ASH, eventus pro hominibus qui non habuerant, ostensi sunt MRD post primum elit.
Ad 3.5 annos post remissionem curationis post-remissionis, LXXXIII% aegrorum cum blinatumomab et chemotherapy tractata adhuc superstites erant, cum tantum 83% aegrorum cum sola chemotherapy tractata adhuc viverent.
Blinatumomab efficax pro MRD-negativo OMNES tam
B-cell ALL is the most common type of ALL in both adults and children. It is a type of sanguinem cancer that spreads quickly and is very dangerous. Chemotherapy is the standard treatment, and it often leads to remission. However, a lot of people get sick again, even if tests done after treatment show no signs of disease.
Medicamenta immuna quaedam promissione demonstraverunt viam cancri tractandi postquam in remissionem processit et periculum demittit de eo quod revertitur.
A genus immunotherapy called a bispecific T-cell engager (BiTE) is what blinatumomab is. It sticks to both T cells and cancer cells at the same time. This makes it easy for T cells to find and kill the cancer cell by bringing them closer together. The drug, which is given through an IV, has been shown to be more effective than chemotherapy at treating B-ALL that has come back in children and young adults who have already been treated for it.
Hoc iudicium, quod curritur per Research Group ECOG-ACRIN Cancri auxilio a NCI, anno 2013 incepit videre si blinatumomab iuvare posset homines qui nuper cum B-cell OMNES diagnostae sunt.
Etiamsi 488 homines in toto iudicio interfuerunt, eventus qui in ASH ostensi erant tantum 224 homines erant in remissione et MRD-negantes post chemotherapy initialem consuetam diaetam. Aegri chemotherapy vel plusquam blinatumomab vel chemotherapy dabantur. Tunc omnes subditi chemotherapy singulis sex mensibus per 2.5 annos obtinuerunt. Nonnulli etiam medullam osseam transferunt, si optimum esse eorum medicus arbitrabatur.
Non solum blinatumomab addens ad chemotherapy meliorem altiore superesset, sed etiam aegros diutius vivere sine carcinomate suo comparavit ad illos qui tantum chemotherapyam acceperunt.
Dr. Litzow dixit neminem ex hominibus, qui blinatumomab ceperint, effectus inexspectatos habere. Nonnulli blinatumomab frequentissimum latus effectus sunt febres, responsa ad infusionem, dolores, infectiones, tremores, et frigora.
